May 26, 2017 8:59 PM ET

Pharmaceuticals

Company Overview of Amaran Biotechnology, Inc.

Company Overview

Amaran Biotechnology, Inc. develops and manufactures glycoprotein drugs for breast cancer. The company offers Haoding (OBI Pharma) Advanced Metastatic Breast Cancer Drugs OBI-822 and OBI-821. Amaran Biotechnology, Inc. was founded in 2010 and is based in Zhubei City, Taiwan.

No. 19 Shengyi 5th Road

Hsinchu County

Zhubei City,  30261

Taiwan

Founded in 2010

Key Executives for Amaran Biotechnology, Inc.

Amaran Biotechnology, Inc. does not have any Key Executives recorded.

Amaran Biotechnology, Inc. Key Developments

Stellar Biotechnologies, Inc. and Amaran Biotechnology, Inc. Enter into Multi-Year Supply Agreement

Stellar Biotechnologies, Inc. and Amaran Biotechnology, Inc., have entered into an exclusive multi-year supply agreement in connection with clinical development studies of immunotherapies for metastatic breast cancer and other cancers. The agreement follows a two-year development collaboration between the companies involving the optimization of manufacturing processes for a KLH-conjugated vaccine known as Adagloxad Simolenin (formerly OBI-822), now in late-stage clinical studies. Adagloxad Simolenin is part of a new class of treatments, known as active immunotherapies, which are designed to stimulate a patient's own immune system to recognize and attack targeted tumor cells. Under the terms of the supply agreement, Amaran has committed to purchase Stellar KLH in amounts necessary to meet its requirements for vaccine production. Stellar will maintain a master file with the U.S.FDA for the KLH product used by Amaran. In addition to Adagloxad Simolenin, the exclusive supply agreement covers cancer immunotherapies and vaccines that combine tumor antigens known as Globo H to one of Stellar's KLH product formulations.

Stellar Biotechnologies, Inc. and Amaran Biotechnology Inc. Provide Update on Collaboration

Stellar Biotechnologies, Inc. provided an update on the company's ongoing collaboration with Amaran Biotechnology, Inc. The alliance between Stellar and Amaran was formed in 2013 to develop and evaluate methods for the manufacture of the OBI-822 immunotherapy, which incorporates Stellar KLHTM as the immune-stimulating carrier molecule. Stellar and Amaran have now completed all primary objectives of the collaboration, which include method development, formulation, and process qualification for GMP-grade Stellar KLHTM and meeting the specifications needed for the production of OBI-822. The next stage of the collaboration will involve scale-up and optimization of processes to commercial manufacturing levels, with the focus on production, quality, and regulatory requirements to support OBI Pharma's planned global Phase III trial and potential future market launch.

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Amaran Biotechnology, Inc., please visit www.amaran.com.tw. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.